Showing results (61-70 of 74) with videos related to

Sort By:
Pageof 8
The American Journal of Pathology|December 24, 1997
Type 2 helper T-cell predominance and high CD30 expression in systemic sclerosisC Mavalia, C Scaletti, P Romagnani, et al.
Clinical and Experimental Rheumatology|October 3, 2009
Vitamin E gel reduces time of healing of digital ulcers in systemic sclerosisG Fiori, F Galluccio, F Braschi, et al.
Arthritis and Rheumatism|March 4, 1998
Circulating Vdelta1+ T cells are activated and accumulate in the skin of systemic sclerosis patientsR Giacomelli, M Matucci-Cerinic, P Cipriani, et al.
The European Respiratory Journal|December 3, 2008
QuantiFERON-TB Gold and the TST are both useful for latent tuberculosis infection screening in autoimmune diseasesF Bartalesi, S Vicidomini, D Goletti, et al.
Annali Italiani Di Medicina Interna : Organo Ufficiale Della Societa Italiana Di Medicina Interna|July 1, 1994
[Patterns of ventricular late potentials in systemic sclerosis: a noninvasive method in the study of cardiac involvement]A Pignone, M Matucci-Cerinic, A Becucci, et al.
Clinical and Experimental Rheumatology|September 8, 2006
Etrurians vs Greeks: May ACE I/D polymorphism still be considered as a marker of susceptibility to SSc?S Guiducci, C Fatini, A Georgountzos, et al.
Scandinavian Journal of Rheumatology|October 26, 2006
Piascledine modulates the production of VEGF and TIMP-1 and reduces the invasiveness of rheumatoid arthritis synoviocytesM Cinelli, S Guiducci, A Del Rosso, et al.
Rheumatology (Oxford, England)|July 7, 2005
Deflazacort modulates the fibrinolytic pattern and reduces uPA-dependent chemioinvasion and proliferation in rheumatoid arthritis synoviocytesA Del Rosso, M Cinelli, S Guiducci, et al.
Clinical and Experimental Rheumatology|September 22, 2005
The fibrinolytic system components are increased in systemic sclerosis and modulated by Alprostadil (alpha1 ciclodestryn)F Bandinelli, F Bartoli, E Perfetto, et al.
Annals of the Rheumatic Diseases|May 19, 2006
EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)W Zhang, M Doherty, E Pascual, et al.
Pageof 8